Last year's flu season hit the U.S. early and hard. Just how hard has now become clear, with the Centers for Disease Control and Prevention reporting there were 381,000 flu-associated hospitalizations. Without a vaccine, things would have been much worse though.
Last winter, Google Flu Trends was shown to be a work in progress when it wildly overestimated incidence of influenza, but its algorithm-based model has considerable potential.
Princeton University will not begin to offer Novartis' meningitis B vaccine to Bexsero to students until next week, but health officials are already considering expanding the campaign to another university. An outbreak at the University of California, Santa Barbara, is the cause of the latest concerns.
As a meningitis outbreak has slowly spread across Princeton University over the past 8 months, the case for vaccinating students has grown stronger. The only hitch is that the vaccine, Novartis' Bexsero, has yet to win approval in the U.S. Now, though, health authorities are willing to work around this obstacle.
While the government shutdown has cast doubt on the Centers for Disease Control and Prevention's (CDC) ability to manage the upcoming flu season, officials can take some solace from last year's efforts. Flu vaccine uptake levels in adults, kids and health workers all trended upward last year.
Congress' failure to find a budget compromise and subsequent government shutdown has left CDC without the staff to carry out many of its functions, including the seasonal influenza program.
Antimicrobial resistance is on the rise in the U.S. and elsewhere, and healthcare providers are running out of drugs in their arsenal to combat some pathogens, leaving patients vulnerable to dangerous infections, according to a new federal report.
GSK will begin adding 2-D barcodes to its Fluarix Quadrivalent 4-in-1 influenza vaccine, which the FDA cleared for shipping on Monday. Over the next 6 months GSK will add the barcode technology to the packaging of more vaccines.
U.S. public health officials have fretted about low use of human papillomavirus (HPV) vaccines among adolescent girls for a few years, but rates were at least trending upwards. Now this slow rise has stalled, though, with the proportion receiving all three doses falling for the first time.
A new paper has validated the Centers for Disease Control and Prevention's 2011 recommendation that males receive the HPV vaccine, particularly men who have sex with men, who are a higher risk group.